Dianthus Therapeutics
DNTH
DNTH
93 hedge funds and large institutions have $139M invested in Dianthus Therapeutics in 2022 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 19 increasing their positions, 30 reducing their positions, and 16 closing their positions.
New
Increased
Maintained
Reduced
Closed
more ownership
Funds ownership: →
less first-time investments, than exits
New positions opened: | Existing positions closed:
less funds holding
Funds holding: →
less capital invested
Capital invested by funds: $ → $
37% less repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 30
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
50% less call options, than puts
Call options by funds: $1K | Put options by funds: $2K
Holders
93
Holding in Top 10
1
Calls
$1K
Puts
$2K
Top Buyers
| 1 | +$5.09M | |
| 2 | +$3.79M | |
| 3 | +$2.09M | |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
+$1.54M |
| 5 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$1.42M |
Top Sellers
| 1 | -$14M | |
| 2 | -$3.27M | |
| 3 | -$1.45M | |
| 4 |
GGHC
Gilder Gagnon Howe & Co
New York
|
-$846K |
| 5 |
Truist Financial
Charlotte,
North Carolina
|
-$566K |